BioCentury | Sep 4, 2020
Product Development

Rain to advance growing precision oncology pipeline with $63M series B

...is also developing small molecule inhibitors of RAD52...
...inhibitor, but will also test a combination of RAD52...
...Neuregulin 1 p53 (TP53)PARP – Poly(ADP-ribose) polymerase RAD52RAD52 homolog Danielle...
BioCentury | Jul 24, 2018
Distillery Therapeutics

Cancer

...INDICATION: Colorectal cancer Cell culture and mouse studies suggest inhibiting RAD52 could help treat FANCM-deficient colorectal...
...treat FANCM-deficient colorectal cancer. In a FANCM-knockout human colorectal cancer cell line, an shRNA targeting RAD52...
...testing RAD52 inhibitors in models of FANCM-deficient colorectal cancer. TARGET/MARKER/PATHWAY: FA complementation group M (FANCM); RAD52 homolog (RAD52)...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

...and PARP in myeloproliferative neoplasms (MPN); SDHB and BCL-2 in multiple myeloma (MM); PARP-1 and RAD52...
...Poly(ADP-ribose) polymerase-1; PRMT5 - Protein arginine methyltransferase 5; RAD51 - RAD51 homolog; RAD52 - RAD52 homolog...
BioCentury | Dec 17, 2015
Distillery Therapeutics

Therapeutics: RAD52 homolog (RAD52); breast cancer 1 early onset (BRCA1); BRCA2

...Cancer INDICATION: Cancer; leukemia In vitro studies identified 6-hydroxy-DL-dopa as an allosteric inhibitor of RAD52 that...
...high throughput screen of a library of drug-like compounds for RAD52 activity, 6-hydroxy-DL-dopa allosterically bound RAD52...
...identifying additional small molecule RAD52 inhibitors that are more amenable than 6-hydroxy-DL-dopa to optimization. TARGET/MARKER/PATHWAY: RAD52 homolog (RAD52)...
BioCentury | Jan 6, 2011
Distillery Therapeutics

Indication: Cancer

...vitro studies suggest that inactivating RAD52 could help treat BRCA2-defective tumors. Small hairpin RNA against RAD52...
...and x-ray-induced chromosomal breaks than cells expressing BRCA2 or RAD52. Next steps could include testing RAD52...
Items per page:
1 - 5 of 5